B+
Bull case
25%
Probability
Target price
$12.00
-30.4% vs current
DYN
Dyne TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$8.00
-53.6% vs current
B-
Bear case
25%
Probability
Target price
$5.00
-71.0% vs current
AI sentiment snapshot
Latest data as of 2025-10-26
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market sentiment is mixed: investors await clinical readouts and are sensitive to dilution risks, producing choppy trading and occasional optimism around partnership rumors [#Company-PR, #Market-News]. Short-term tone leans cautious due to funding needs, while long-term sentiment depends on pivotal data outcomes [#SEC-10Q].
RankAlpha Sentiment AI - 2025-10-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventPivotal or registrational trial readouts for DMD/other programsHigh impact
Upcoming clinical readouts or data updates from lead Duchenne muscular dystrophy (DMD) programs could re-rate the stock if results show clear efficacy/safety improvements vs. SOC [#PR-Company, #10-K-2024].
-catalystFunding / dilution eventsHigh impact
Equity raises or convertible financings to fund trials can dilute shareholders and pressure the share price; monitor SEC filings for shelf takedowns [#SEC-10QpFiling].
2026-03-31catalystNear-term data from early-stage SRP- or AAV-derived programsHigh impact
Early-stage biomarker or safety updates from preclinical/Phase 1 studies (e.g., target engagement, tolerability) may cause short-term volatility [#PR-Company, #SEC-8K].
Recommendation
N/A
No formal recommendation provided.
As of 2025-10-26 • Updated nightlySource: Internal modelMethodology